Key facts
- Dermaweave’s last known valuation is $5.3M (Jan 2026).
- It has raised $1.4M; the latest was Later Stage VC ($670K) in Jan 2026.
- Notable investors include Innovate UK, SFC Capital, Development Bank of Wales, Engineering and Physical Sciences Research Council, Adrian de Courcey — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Dermaweave
- ·The full record, as it builds
Funding rounds
No funding rounds for Dermaweave are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dermaweave
Developer of wound dressing device technology designed for contactless application of wound dressings. The company's platform utilizes electrical voltages to extrude fine fibers from various fluids, producing non-woven meshes composed of synthetic or natural materials, with or without active ingredients, enabling healthcare providers to create advanced tissue repair dressings directly at the wound site for improved adaptability and treatment precision.
- Sector
- Healthcare
- HQ
- Baglan, United Kingdom
- Founded
- 2021
- Employees
- 4
- Website
- dermaweave.co.uk/
- Ownership
- Privately Held (backing)
Dermaweave doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dermaweave shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dermaweave in its N-PORT filings yet. We sweep new filings monthly.